PICLIB 75MG CAPS 21'S

About

PICLIB 75MG CAPS 21'S, likely a Cyclin-Dependent Kinase (CDK) 4 and 6 inhibitor, represents a significant advancement in targeted cancer therapy. This medication works by selectively inhibiting the activity of CDK4 and CDK6, enzymes that play a crucial role in regulating cell cycle progression. By blocking these kinases, PICLIB prevents cancer cells from advancing from the G1 phase to the S phase of the cell cycle, thereby halting their proliferation. This targeted mechanism of action primarily affects rapidly dividing cancer cells, offering a more specific approach compared to traditional chemotherapy.

It is predominantly used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, typically in combination with endocrine therapy. The synergistic effect with endocrine agents helps to overcome resistance mechanisms and significantly improves progression-free survival in eligible patients. Regular monitoring for potential side effects, particularly myelosuppression, is essential to ensure patient safety and optimize treatment outcomes.

Uses

• Treatment of HR+/HER2- metastatic breast cancer
• Used in combination with endocrine therapy
• Management of advanced breast cancer progression
• Delaying disease progression in eligible patients

Directions For Use

Take orally once daily with food, as directed by your oncologist. Follow the prescribed dosing schedule, including any treatment breaks.

Benefits

• Significantly improves progression-free survival
• Targeted therapy with a specific mechanism of action
• Oral administration offers patient convenience
• Synergistic effect when combined with endocrine therapy
• Reduces tumor growth and spread in advanced breast cancer
• Extends the period of disease control for patients

Side Effects

• Neutropenia
• Leukopenia
• Fatigue
• Nausea
• Diarrhea
• Stomatitis
• Hair thinning
• Rash
• Elevated liver enzymes
• Infections
• Pulmonary embolism (rare)
• Interstitial lung disease (rare)

Safety Measures

• Alcohol - No specific contraindication, but moderation is advised as alcohol may exacerbate fatigue or gastrointestinal upset.
• Pregnancy - Contraindicated during pregnancy due to potential teratogenic effects. Women of childbearing potential must use effective contraception.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if it is excreted in human milk and could cause serious adverse reactions in the infant.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustment may be required in moderate to severe impairment, and liver function should be monitored.
• Kidney - Use with caution in patients with renal impairment. Dose adjustment may be required in severe impairment, and renal function should be monitored.
• Lung - Monitor for signs and symptoms of interstitial lung disease or pneumonitis. Discontinue treatment if suspected and manage appropriately.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.